SearchCME LoginCE Login Show Cart
NACE: National Association For Continuing Education 866-266-6223 9a am to 5 pm EST Mon-Fri
CME Course Description
   
Login to view
Course Activities.

CME Live Virtual Conferences

Go Back


Course Director
Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL



Title
: Challenges in Pulmonary and Critical Care 2017: 11th Annual Symposia Sunrise, FL
Activity/Course #:
: 12.02.17PULM
Cost:
: Free
Release/Start Date:
: Dec 02 2017
Expiration Date:
: Dec 02 2017
Topics:
: Pulmonology
Target Audience:
: Pulmonologists, Hospitalists, Primary Care Providers
Format:
: Live Pulmonary Conference
Estimated Time To Complete CME Activity:
: 7.5 hours
Credit(s):
: 7.5 AMA PRA Category I Credit(s)
7.5 AANP Contact hour(s)
Hardware/Software Requirements:

Saturday, December 2, 2017
Doubletree by Hilton Sunrise
13400 W Sunrise Blvd
Sunrise, FL 33323
(954) 851-1020

Registration Fee

There is no registration fee for this activity.

Special Accommodations


NACE fully complies with the legal requirements of the Americans with Disabilities Act. Any activity registrant who feels s/he may need accommodations based on the impact of a disability should contact NACE to discuss your specific need.

Event Parking

Complimentary self-parking is available at the hotel.

Program Summary

The goal of this CME activity is to provide an update in the prevention, diagnosis and management of pulmonary disease to pulmonologists, hospitalists, primary care providers and other health care providers who treat patients with pulmonary diseases.  Current findings in pulmonary research in topics such as Pulmonary Hypertension, COPD, Idiopathic Pulmonary Fibrosis, Alpha One Anti-trypsin Deficiency, Sarcoidosis, Lung Cancer, Asthma, and Venous Thromboembolism will be presented.

We have recruited a faculty of well-known thought leaders and experienced teachers who, as clinicians themselves, understand the challenges you face every day as a healthcare provider. Our faculty will be at your disposal to provide evidence-based science, current treatment guidelines, discuss challenging cases, and provide answers for you that can ultimately lead to better health care for your patients. The presentations will include several interactive cases and discussion sessions to keep you actively learning.

Please join us and become an active participant in this one-day learning community of your peers.

Learning Objectives
At the conclusion of this program, participants should be able to:

1. Discuss the diagnosis and classification of pulmonary hypertension according to the World Health Organization (WHO) clinical classification system; Outline an approach to rule out and appropriately manage chronic thromboembolic pulmonary hypertension (CTEPH), if present; Recognize the role of upfront, early combination and goal-oriented therapy for pulmonary arterial hypertension (PAH); Describe the management of adverse events with PAH therapies and strategies to improve patient adherence.

2. Describe strategies of care in COPD to improve diagnosis and ongoing symptom assessment; Tailor COPD therapy to the individual patient following current therapeutic strategies accounting for unique patient needs and characteristics, including the appropriate use of inhaled therapeutic devices; Discuss the role of evolving bronchoscopic techniques for lung volume reduction; Collaborate with members of interprofessional health care team for to create an effective patient-centered, chronic disease management program.

3. Describe the typical clinical presentation of a patient with possible idiopathic pulmonary fibrosis (IPF); Discuss the diagnostic approach to a patient with suspected IPF; Discuss and contrast the available pharmacotherapeutic options for patients with IPF; Discuss and contrast the available nonpharmacotherapeutic options for patients with IPF.

4. Discuss the pathophysiology of alpha1-antitrypsin deficiency (AATD); Learn how to diagnose AATD patients; Incorporate AATD testing into chronic obstructive pulmonary disease (COPD) management algorithms; Evaluate treatment options for patients with AATD.

5. Describe the pathophysiology and the epidemiology or Sarcoidosis; Understand the up-to-date methodology for diagnosis of Sarcoidosis; Review our current understanding of the treatments considered, including steroids, mineralocorticoid receptor agonists and other agents.

6. Discuss the screening of patients for lung cancer; Describe the current classification of lung cancer patients; Explain new treatment options and genetics for lung cancer and novel genetic screenings; Discuss future developments in the treatment of lung cancer.

7. Define severe/persistent asthma; Discuss the different phenotypes of severe asthma; Describe the pathophysiology of severe asthma with an emphasis in type 2 inflammation; Discuss emerging data supporting the use of biologic therapies that target specific cytokines involved in type 2 inflammation, such as interleukin-4 (IL-4), IL-5, and IL-13.

8. To be Determined

9. Recognize risk factors and clinical symptoms or signs suggestive of venous thromboembolism (VTE); Describe the pathophysiology of VTE and rationale for extended anticoagulation; Review the available data on the use of the new oral anticoagulants in treatment of venous thromboembolic disease; Discuss evidence-based strategies to reduce recurrence of VTE in select patients.

Agenda

7:30-8:00

  Continental Breakfast and Registration
8:00-8:10   Welcome Remarks
Franck Rahaghi, MD, MHS, FCCP
8:10-9:00  

Pulmonary Hypertension: The Era of Combination Therapy
Jinesh P. Mehta, MD

9:00-9:50  

COPD – New Management
Anas Hadeh, MD, FCCP

9:50-10:10   Break
10:10-11:00   Idiopathic Pulmonary Fibrosis: New Advances in Therapy
Joao A. de Andrade, MD
11:00-11:50  

Alpha-1 Antitrypsin Deficiency: Challenges in Diagnosis and Treatment
Charlie Strange, MD

 11:50-12:40 Sarcoidosis: Update 2017
Franck Rahaghi, MD, MHS, FCCP
 12:40-1:25 

Lunch

 1:25-2:15 Lung Cancer and Precision Medicine
Sajive Aleyas, MD
2:15-3:05
 Asthma Frontiers: Novel Therapies
Frank Eidelman, MD
3:05-3:20   Break
 3:20-4:10 To Be Determined
4:10-5:00  

Venous Thromboembolic Disease - Diagnosis and Managing Anticoagulation
Carmel Celestin, MD

 5:00-5:15

  Program Summary and Closing Remarks
Franck Rahaghi, MD, MHS, FCCP
*Agenda subject to change.

Faculty

Sajive Aleyas, MD
Director, Interventional & Advanced Diagnostic Bronchology Clinic
Director, Respiratory Center Lung Cancer Program
Department of Pulmonary & Critical Care
Cleveland Clinic Florida
Weston, FL

Carmel Celestin, MD
Department of Vascular Medicine
Cleveland Clinic Florida
Weston, FL

Joao A. de Andrade, MD
Professor of Medicine
Director, Pulmonary Disease and Critical Care Medicine Training Program
Director, Interstitial Lung Disease Program
University of Alabama at Birmingham
Birmingham, AL

Frank Eidelman, MD
Chair, Department of Allergy & Immunology
Cleveland Clinic Florida
Weston, FL

Anas Hadeh, MD, FCCP
Director, Pulmonary and Critical Care Medicine Fellowship Program
Affiliate Assistant Professor of Clinical Biomedical Science
FAU Charles E. Schmidt College of Medicine
Cleveland Clinic Florida
Weston, FL

Jinesh P. Mehta, MD
Director, ICU Operations / MICU
Pulmonary & Critical Care Medicine
Cleveland Clinic Florida
Weston, FL

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Charlie Strange, MD
Professor of Pulmonary and Critical Care Medicine
Medical University of South Carolina
Charleston, SC

Planning Committee

Gregg Sherman, MD
Chief Medical Officer
National Association for Continuing Education
Plantation, FL

Franck Rahaghi, MD, MHS, FCCP
Director of Advanced Lung Disease Clinic
Director, Pulmonary Hypertension Clinic
Head of Alpha-1 Foundation Clinical Resource Center
Chairman, Dept. of Pulmonary and Critical Care
Cleveland Clinic Florida
Weston, FL

Sheila Lucas, CWEP
Activity Director
National Association for Continuing Education
Plantation, FL

Michelle Frisch, MPH, CHCP
National Association for Continuing Education
Plantation, FL

Harvey C. Parker, Ph.D., CHCP
National Association for Continuing Education
Plantation, FL

Sponsored and Certified By
National Association for Continuing Education
Accreditation Designation Statement
The National Association for Continuing Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The National Association for Continuing Education designates this live activity for a maximum of 7.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

National Association for Continuing Education is approved as a provider of nurse practitioner continuing education by the American Association of Nurse Practitioners. AANP Provider Number 121222. This program has been approved for 7.5 contact hours of continuing education (which includes pharmacology hours).
Faculty Disclosure Policy
It is the policy of the accredited providers to ensure fair balance, independence, objectivity and scientific rigor in all activities. All faculty participating in CME activities sponsored by the accredited providers are required to present evidence-based data, identify and reference off-label product use and disclose all relevant financial relationships. Faculty disclosure will be provided in the activity materials.
Commercial Support
Challenges in Pulmonary & Critical Care 2017 is supported by an educational grant from Actelion Pharmaceuticals US, Inc.; in part, by an educational grant from Bayer Healthcare Pharmaceuticals, Inc.; an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc.; an educational grant from Grifols; an educational grant from Mallinckrodt Pharmaceuticals; and by an independent medical educational grant from Shire.